ロード中...
Hepatitis B reactivation during or after direct acting antiviral therapy – implication for susceptible individuals
INTRODUCTION: The FDA issued a warning following 24 cases of HBV reactivation during DAA therapy for HCV, including individuals with inactive, occult and past HBV infection. Clinical presentations ranged from asymptomatic fluctuations in HBV DNA to fulminant hepatic failure, liver transplantation an...
保存先:
| 出版年: | Expert Opin Drug Saf |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5589072/ https://ncbi.nlm.nih.gov/pubmed/28471314 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14740338.2017.1325869 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|